Opportunistic Infections ( CROI ) this week in Boston , Mass . ( three percent and two percent , respectively ) . required initiation of lipid-lowering therapy in the study. patients in the lopinavir / r arm discontinued the study therapy before week 48. dose combination of emtricitabine 200 mg / tenofovir disoproxil fumarate 300 mg. of less than 50 copies / mL at 48 weeks. viral load in the twice-daily lopinavir / r arm. total bilirubin greater than 2.5 times the upper limit of normal. the upper limit of normal ) were similar between treatment arms. and CD4 + category within the lopinavir / r arm ( p = 0.0085 ) . infected patients and is administered once-daily in all patient populations. trials in both patients who have taken or have never taken anti-HIV medicines .